FP7-BALANCE WP5 LEAD:EDINBURGH AIM: Safety and efficacy of AMC-HepRG BAL in the porcine model of paracetamol-induced ALF Start date : M12 Edinburgh team:

Slides:

Advertisements

Similar presentations

An Outline for: A User-Based Systems Approach to the Evaluation, Selection, and Institutionalization of Safer Medical Devices.

Advertisements

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.

Current and Upcoming Clinical Trials Now, let’s consider 2 treatments where few or no photoreceptor cells remain alive. Possible treatments here would.

What is a project? Project Management Institute definition

Date Name Speaker Institute / University. Raman4Clinics – Raman-Based Applications for Clinical Diagnostics Based on Raman Spectroscopy and to overcome.

Good Manufacturing Practices for Blood Establishments

C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.

BALANCE WP 6: Preparation clinical trial (M9-M31) (AMC, HepArt & UEDIN) Objectives Objective: To obtain regulatory approval for the planned phase I/IIa.

Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.

Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Stefan Franzén Introduction to clinical trials.

Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.

PROPOSAL FOR TIME-LINE AND ROAD-MAP OF STEM CELL R&D AND SERVICE AT RSCM/FKUI.

Human Embryonic Stem Cells: Considerations for Therapeutic Development Jane Lebkowski Ph.D. Geron Corporation Cell, Tissue and Gene Therapy Advisory Committee.

Evaluating A Systemic Therapy Psoriasis 1.Efficacy 2.Safety 3.Labeling.

Cardiology Clinical Assessment & Treatment Service …coming soon!

Accreditation Canada Critical care team By Norah Khathlan MD Assistant Prof. Pediatrics Consultant Pediatric Intensivist Director PICU January/ 2009.

Managing the Information System Project Dr. Dania Bilal IS 592 Spring 2005.

FACULTY OF MEDICINE The use of Cochrane breast cancer reviews by guideline developers and Cochrane (public) users Cochrane Breast Cancer Group, NHMRC Clinical.

Diagnosing cardiac disease states using a minimal cardiovascular model Christina Starfinger Wednesday, 21 March 2007 HRSC Scientific Meeting.

Programme for Health Services Improvement Primary and Community Services Workshop February 2008.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

1 Module 7 Discharge Planning Managing the Transition from Inpatient to Outpatient Care Diabetes Special Interest Group Georgia Hospital Association.

Gabriela Franco Salinas Bas Leewis Rachel Pijls October 5th, 2012 BALANCE-project.

ITU Journal Club: Dr. Clinton Jones. ST4 Anaesthetics.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

A. Veneziani, A. Appicciafuoco, F. Picca, A. Molisso, L. Garofolini, B. Librandi, I. Frati, V. Fusari Nuovo San Giovanni di Dio Hospital Florence - Italy.

Setting Goals of Care. SSC 2012 Guidelines Setting Goals of Care We recommend that goals of care and prognosis be discussed with patients and families.

Workpackage 2: Review and quantitative evaluation of the effectiveness of interventions University of Reading.

The Guildford Experience Enhanced Recovery: The story so far…. Dr Wendy King Anaesthetic Department, Royal Surrey County Hospital, Guildford, UK January.

Dr Mark Chong National University of Singapore Dept of Obstetrics and Gynaecology.

NET Registry in Greece Dr Kalliopi Pazaitou-Panayiotou, MD, PhD Departement of Endocrinology-Endocrine Oncology Theagenion Cancer Hospital Thessaloniki,

AMI -RAVREDA – USAID Project report, Colombia March 2009 Preliminary results on efficacy and Safety of Coartem ® on the treatment of Acute Uncomplicated.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

Issues in Treatment Study Design John Whyte, MD, PhD Neuro-Cognitive Rehabilitation Research Network Moss Rehabilitation Research Institute.

Fundamental of research Dr. Ali Abd El-Monsif Thabet.

. Clinical Trials Copyright © Texas Education Agency, All rights reserved.

Drug Development Process Stages involved in Regulating Drugs

Vaccine Company Perspective Dr Gaurav Gupta, ZYDUS CADILA

BCT Bortezomib Consolidation Trial

Ensuring Successful Technology Transfer for Clinical Manufacture

Chapter 4 Research Methods in Clinical Psychology

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

Research Questions Does integration of behavioral health and primary care services, compared to simple co-location, improve patient-centered outcomes in.

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

Clinical Trials — A Closer Look

Using Observation to Enhance Supervision CIMH Symposium Supervisor Track Oakland, California April 27, 2012.

3Biostatistics, Pacific University, Forest Grove, Oregon, USA

EU funding opportunities

Future Leaders In Research Programme (FLIR) Session 1

Guillaume Bouguen, Barrett G. Levesque, Brian G

Metastatic Renal Cell Carcinoma

Delete and replace with your own name and institution

To gain consensus of the patient assessment skills required by pharmacist independent prescribers (PIPs) to inform a competency framework for the prescribing.

PN-III-ID_PCE_ Contract: 179/2017

The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation

FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health

L Meng, P.M. Heerdt British Journal of Anaesthesia

Neuroscience Biomarker Program

Machine Learning for Individualized Medicine

CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)

L Meng, P.M. Heerdt British Journal of Anaesthesia

T Salah, MD., M Saber, MBBCh., T ElTaweil, MD. and N Rasmy,MD.

Delivering a High quality Intraoperative Cell Salvage Service.

Fig. 3. Strategy for the development of probiotics as prophylactic and therapeutic microbial agent. More stress should be laid on strain specificity and.

Presentation transcript:

FP7-BALANCE WP5 LEAD:EDINBURGH AIM: Safety and efficacy of AMC-HepRG BAL in the porcine model of paracetamol-induced ALF Start date : M12 Edinburgh team: Prof Hayes, Dr Plevris, Dr L Nelson (Hepatology) Dr A Lee, Dr A Hay ( Anaesthetics) Prof E Clutton, Dr T King, Dr M Eddleston ( Vet School/Roslin Institute) 2 post-docs (tba)

Objectives To obtain proof of principle of safety and efficacy of HepaRG-BAL in a porcine model of ALF Specific objectives: Task 5.1: To develop a reproducible invasively- monitored model of paracetamol-induced ALF in 35 kg Gottingen minipigs Task 5.2: To assess clinical and biochemical parameters in paracetamol-induced ALF pigs under ICU monitoring and therapy conditions. Task 5.3: To assess efficacy/ safety of HepaRG-BAL in three groups of 7 pigs

21 Pigs will be divided into 3 groups, under 3 different BAL system conditions: Clinical-grade (GMP) BAL Systems will be utilized; - Standard ICU/ Clinical treatment (n=7); - BAL System treatment - WITHOUT HepaRG cells (n=7) - BAL System treatment - WITH HepaRG cells (n=7); *A preliminary phase of 5-7 animals to establish the ALF model will start as soon as feasible. *Total expected number of animals 30 ( 2-3 extra animals as contigency). *Experiments will last up to 48 hours, and any animals surviving at this time-point are euthanised.

DELIVERABLES D5.1 Establishment of a reproducible invasively-monitored minipig model of paracetamolinduced ALF and related protocols and monitoring systems; M15 -D5.1.1 Robust reproducible paracetamol-induced ALF Model in 35 kg minipigs; M15 D5.1.2 Protocol of intensive care treatment of ALF pigs; M15 - D5.1.3 Monitoring system of haemodynamics, ICP and blood chemistry; M15 D5.2 Report on variability of survival time of paracetamol induced ALF in mini-pigs; M15 D5.3 Report on efficacy/ safety of HepaRG-BAL in three groups of 7 animals, M24 D5.3.1 Knowledge about the efficacy and safety of the HepaRG BAL as a treatment of ALFin mini-pigs; M21 D5.3.2 Functional Genomics Data Bioinformatics Analysis/ Report Completed; M24 D5.3.3 Data from statistical analysis, report Completed; M24